Literature DB >> 9671929

Actions of endothelin-1, 2, and 3 in the microvasculature of bone.

P J Briggs1, C G Moran, M B Wood.   

Abstract

Endothelins have recently been associated with hypoxia-related vascular smooth-muscle constriction and with the so-called no-reflow phenomenon following reperfusion. Their action is tissue dependent. The role of endothelins on vascular smooth muscle in bone is unknown. An ex vivo perfusion model was used to investigate the effects of the three different endothelins on the vascular resistance in the canine tibia. Endothelin-1 and endothelin-2 had molar potencies similar to that of norepinephrine, whereas endothelin-3 was less potent. Tachyphylaxis to the same dose of endothelin-1 did not occur. The calcium channel blocker, diltiazem, attenuated (45% reduction) the vasoconstrictor responses to norepinephrine (p < 0.005) but had a smaller effect (24% reduction) on the responses to endothelin (p < 0.025). Vascular smooth muscle in bone appears to have endothelin receptors that are similar to those in other organs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671929     DOI: 10.1002/jor.1100160310

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  3 in total

1.  Characterization of bone perfusion by dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography in the Dunkin-Hartley guinea pig model of advanced osteoarthritis.

Authors:  Jonathan P Dyke; Michael Synan; Paula Ezell; Douglas Ballon; Jennifer Racine; Roy K Aaron
Journal:  J Orthop Res       Date:  2014-11-19       Impact factor: 3.494

2.  Generation and characterization of an endothelin-2 iCre mouse.

Authors:  Joseph A Cacioppo; Yongbum Koo; Po-Ching Patrick Lin; Arnon Gal; CheMyong Ko
Journal:  Genesis       Date:  2015-02-12       Impact factor: 2.487

3.  Comparison of plasma endothelin levels between osteoporotic, osteopenic and normal subjects.

Authors:  Hasan Hilmi Muratli; Levent Celebi; Onur Hapa; Ali Biçimoğlu
Journal:  BMC Musculoskelet Disord       Date:  2005-09-20       Impact factor: 2.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.